Optimized Multi-Epitope Norovirus Vaccines Induce Robust Humoral and Cellular Responses in Mice.

Area of Science:

• Immunology
• Vaccinology
• Computational Biology

Background:

• Norovirus GII.4 poses a significant global health risk.
• Lack of licensed vaccines is attributed to rapid viral evolution and high mutation rates.

Purpose of the Study:

• To rationally design and validate multi-epitope vaccine candidates against Norovirus GII.4.
• To utilize computational immunoinformatics and in vivo evaluation for vaccine development.

Main Methods:

• Employed reverse vaccinology to identify optimal norovirus GII.4 epitopes.
• Designed four vaccine constructs with varying epitope topologies and adjuvants.
• Assessed immunogenicity in mice using ELISA and ELISPOT for humoral and cellular responses.

Main Results:

• Successfully produced three vaccine candidates (NV1, NV4, NV5) inducing cross-reactive antibodies.
• Different construction strategies influenced immune responses: NV5 (highest antibody titers), NV1 (strongest cellular response), NV4 (most rapid response).
• In silico analysis supported NV1's superior capacity for cellular immunity via interaction with TLR3.

Conclusions:

• A rational multi-epitope vaccine design workflow successfully translated computational design to functional vaccines.
• Optimizing adjuvant selection and epitope construction is critical for next-generation norovirus vaccines.